New drug study aims to control advanced breast cancer
NCT ID NCT06301438
Summary
This study is testing how well the drug dalpiciclib works to control advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers will follow 103 patients in real-world settings to see how long the drug keeps the cancer from worsening and monitor any side effects. The goal is to gather practical evidence about this treatment option for patients with this specific type of advanced breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.